Screener
Palvella Therapeutics PVLA Total Liabilities & Equity
Total Liabilities & Equity at other companies
Other financials
Where this comes from
Reported directly by Palvella Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The source filing: Palvella Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 8:30 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-210463
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Commitments and contingencies (Note 8) | ||
| Stockholders’ equity: | ||
| Common stock, $0.001 par value; 200,000,000 shares authorized; 14,313,659 and 12,380,933 shares issued and outstanding at March 31, 2026 and December 31, 2025 | 14 | 12 |
| Additional paid-in capital | 383,421 | 163,338 |
| Accumulated other comprehensive (loss) income | 95 | 83 |
| Accumulated deficit | (151,217) | (135,450) |
| Total stockholders’ equity | 232,313 | 27,983 |
| Total liabilities and stockholders’ equity | $263,759 | $59,559 |
Item 1. Financial Statements.
FAQ
- What is Palvella Therapeutics's total liabilities & equity?
- Palvella Therapeutics (PVLA) reported total liabilities & equity of $263.76M in Q1 2026.
- How has Palvella Therapeutics's total liabilities & equity changed year-over-year?
- Palvella Therapeutics's total liabilities & equity increased by 232.0% year-over-year, from $79.44M to $263.76M.
- What is the long-term trend for Palvella Therapeutics's total liabilities & equity?
- Over 5 years (2020 to 2025), Palvella Therapeutics's total liabilities & equity has grown at a -10.7% compound annual growth rate (CAGR), from $105.01M to $59.56M.
- What does total liabilities & equity mean?
- Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.
Ask your AI about Palvella Therapeutics's total liabilities & equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude